Gene therapy for Type 1 diabetes

E. S. Fenjves, Camillo Ricordi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In Type 1 diabetes, autoimmunity destroys the insulin-producing β-cells of the pancreas, which are located in clusters called 'islets of Langerhans'. Exogenous insulin replacement therapy seldom maintains ideal metabolic control in patients with this disease and consequently, chronic complications progressively develop in many of them. Recently, much of the research concerning the treatment of Type 1 diabetes has been aimed towards the development of gene therapy. The understanding of molecular approaches, such as gene transfer using viral and non-viral delivery systems, are providing novel therapeutic strategies towards a cure for this disease. This review gives an overview of recently filed patents that relate to gene therapy and Type 1 diabetes.

Original languageEnglish
Pages (from-to)325-331
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Volume10
Issue number3
StatePublished - Jan 1 2000

Fingerprint

gene therapy
Type 1 Diabetes Mellitus
Genetic Therapy
chronic illness
Insulin
Disease
Patents
Autoimmunity
Islets of Langerhans
patent
Pancreas
Chronic Disease
Therapeutics
Research
Genes

Keywords

  • β-cells
  • Gene transfer
  • Genetic engineering
  • Genetic vectors
  • Insulin dependent diabetes mellitus (IDDM)
  • Islets of Langerhans

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

Gene therapy for Type 1 diabetes. / Fenjves, E. S.; Ricordi, Camillo.

In: Expert Opinion on Therapeutic Patents, Vol. 10, No. 3, 01.01.2000, p. 325-331.

Research output: Contribution to journalArticle

Fenjves, E. S. ; Ricordi, Camillo. / Gene therapy for Type 1 diabetes. In: Expert Opinion on Therapeutic Patents. 2000 ; Vol. 10, No. 3. pp. 325-331.
@article{929dc084a18240f0b747d7b0c14c8b8c,
title = "Gene therapy for Type 1 diabetes",
abstract = "In Type 1 diabetes, autoimmunity destroys the insulin-producing β-cells of the pancreas, which are located in clusters called 'islets of Langerhans'. Exogenous insulin replacement therapy seldom maintains ideal metabolic control in patients with this disease and consequently, chronic complications progressively develop in many of them. Recently, much of the research concerning the treatment of Type 1 diabetes has been aimed towards the development of gene therapy. The understanding of molecular approaches, such as gene transfer using viral and non-viral delivery systems, are providing novel therapeutic strategies towards a cure for this disease. This review gives an overview of recently filed patents that relate to gene therapy and Type 1 diabetes.",
keywords = "β-cells, Gene transfer, Genetic engineering, Genetic vectors, Insulin dependent diabetes mellitus (IDDM), Islets of Langerhans",
author = "Fenjves, {E. S.} and Camillo Ricordi",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "325--331",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Gene therapy for Type 1 diabetes

AU - Fenjves, E. S.

AU - Ricordi, Camillo

PY - 2000/1/1

Y1 - 2000/1/1

N2 - In Type 1 diabetes, autoimmunity destroys the insulin-producing β-cells of the pancreas, which are located in clusters called 'islets of Langerhans'. Exogenous insulin replacement therapy seldom maintains ideal metabolic control in patients with this disease and consequently, chronic complications progressively develop in many of them. Recently, much of the research concerning the treatment of Type 1 diabetes has been aimed towards the development of gene therapy. The understanding of molecular approaches, such as gene transfer using viral and non-viral delivery systems, are providing novel therapeutic strategies towards a cure for this disease. This review gives an overview of recently filed patents that relate to gene therapy and Type 1 diabetes.

AB - In Type 1 diabetes, autoimmunity destroys the insulin-producing β-cells of the pancreas, which are located in clusters called 'islets of Langerhans'. Exogenous insulin replacement therapy seldom maintains ideal metabolic control in patients with this disease and consequently, chronic complications progressively develop in many of them. Recently, much of the research concerning the treatment of Type 1 diabetes has been aimed towards the development of gene therapy. The understanding of molecular approaches, such as gene transfer using viral and non-viral delivery systems, are providing novel therapeutic strategies towards a cure for this disease. This review gives an overview of recently filed patents that relate to gene therapy and Type 1 diabetes.

KW - β-cells

KW - Gene transfer

KW - Genetic engineering

KW - Genetic vectors

KW - Insulin dependent diabetes mellitus (IDDM)

KW - Islets of Langerhans

UR - http://www.scopus.com/inward/record.url?scp=0033998153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033998153&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 325

EP - 331

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 3

ER -